text:
Arrest Warrant Issued For Cowboys LB Sam Williams Over Car Accident
The Cowboys lost their season finale to the Commanders while the Eagles and 49ers both won their finale's which means the Cowboys will face the Tom Brady and the Buccaneers in Tampa on Monday night in the Wild Card game.
They would love to focus on nothing but that however they can't because of rookie LB Sam Williams.
As reported by TMZ, there is an arrest warrant for Williams from the Plano Police Department stemming from a car crash in December.
An arrest warrant has been issued for Dallas Cowboys rookie Sam Williams, TMZ Sports has learned … over his alleged role in a violent car crash last month.
The Plano Police Department tells us the misdemeanor warrant is for reckless driving … though further details surrounding the allegations against Williams were not made immediately available.
According to a police spokesperson, "at this time, there is no plan to find and arrest" Williams … as the 23-year-old football player "has been contacted to turn himself in."
As we reported, Williams slammed his black Corvette into another vehicle at around 2:15 PM in Plano, Texas on Dec. 22. Pictures from the scene showed the collision caused serious damage, leaving debris all over the roadway.
Williams missed one game due to the accident but luckily no one was hurt.
Flip the page to see more.
In this article:Cowboys, NFL, sam williams


Counted among her many regional credits are more than 30 Shakespearean productions. She has appeared as Rosalind in As You Like It, Kate in The Taming of The Shrew, Goneril in King Lear, and as Lady Macbeth.
A trained, lyric soprano and versatile musical performer, Jean has played the title role in the musical adaptation of Jane Eyre, Cinderella in Into the Woods, Audrey in Little Shop of Horrors and Lilli Vanessi in Kiss Me Kate.
Her New York Credits include Off-Broadway productions at Soho Rep., The Lucille Lortel, Town Hall, The York Theatre, Lamb's Theatre and with the Protean Theatre Company as well as numerous Off-Off Broadway Productions. She has also worked as an actor and director in several productions with the award winning Theaterworks/USA. She directed The Merry Wives of Windsor for the Stella Adler Studio.
Her film work includes the cult horror classic The Deadly Spawn, as well as The Mind's Eye, Bullets Over Broadway, and Whiskey School.


The Editors have selected their choice articles from those published in Political Analysis. These represent papers that the Editors see as providing an especially significant contribution to political methodology.
The Editors' Choice Articles are freely available below.


We are excited to announce that the Danish translation is now available online at urantia.org/da. Our translator, Jean Ascher, would love to hear feedback on his work. Please help spread the word to any readers you know, encourage them to visit the site, and send feedback to either Tamara Strumfeld at [email protected] or Jean at [email protected]. Thank you!


text:
Chorley boxer Jack Catterall eyeing world title unification clash with Josh Taylor
Jack Catterall
Chris Boden
If everything plays out according to plan, Chorley's Jack Catterall would like to be contemplating a world title unification clash against Josh Taylor in the not too distant future.
There are several obstacles standing in the way of such a prospect at present, not least the fact that Catterall has got his mandatory challenge to the WBO world super lightweight champion Maurice Hooker to navigate first.
Taylor, meanwhile, is heavily embroiled in the World Boxing Super Series, where the Scot is scheduled to take on Ivan Baranchyk for the IBF belt at the semi-final stage in Glasgow next month.
If successful, the Edinburgh man will face either Regis Prograis or Kiryl Relikh in the final, with the WBA belt also on the line.
Catterall makes Taylor the favourite to emerge from the series with the bounty.
"The World Boxing Super Series is going on in the background in the meantime and the favourites to win it in my book are either Josh Taylor or Regis Prograis," reasoned the 23-0 Catterall, ahead of his own return to the ring on April 27 at Wembley.
"I do pick Josh over Prograis slightly, although I have not seen too much of the American.
"My ideal scenario would be for me to win my world title and Josh to win the WBSS. Then we could get together for a unification fight.
"I've thought about fighting Josh because I've got to be looking at all the guys in the top ten in my division.
"Everyone is with different promoters but these fights are always possible. For me it is an obvious fight for the future," added the 25-year-old, who clearly backs himself against the best the division has to offer.
"I have definitely got the beating of him, and I think I have got the beating of all the guys if I prepare right."
In the meantime, Catterall will keep busy ahead of his shot at Hooker with a slot on the card at the SSE Arena, live on BT Sport. It is an assignment he views as essential but one he must view with caution given that his big opportunity is firmly on the horizon.
"I am definitely happy and grateful for the opportunity to get a fight at Wembley because it will keep me in a good place physically and mentally. I am under no illusion going into this fight that I have got to treat every one like a world title.
Chorley boxer Stuart Maddox to visit Houses of Parliament to spread his anti-knife crime campaign message
"I'm hoping to pick up a good win on April 27 and really kick on from then. It is a catch 22 because I can't sit on the fence, not be active and earn no wages until my shot. I've just got to get a win and go from there."
Debenhams confirms 19 UK stores set to close in January 2020 - the list in full

redpajama_set_name: RedPajamaCommonCrawl


Titanium alloy powder is made from titanium alloy scrap ( comes form the surface of pure ingot or bar) or titanium alloy bar. The particle shape has two: irregular and spherical. Titanium alloy powder is typically used in powder metallurgy, spray coating, etc.
As one of the professional titanium alloy powder, titanium alloy scrap powder, spherical ti6al4v eli powder, spherical alloy powder,titanium metal powder manufacturers and suppliers in China, TC Titanium can offer you high quality and fast delivery products in stock. If you want to wholesale good quality titanium alloy powder, titanium alloy scrap powder, spherical ti6al4v eli powder, spherical alloy powder,titanium metal powder enjoying hot sales around the world at low price, please feel free to contact our distributor or our factory.


Every once in awhile, we humans start to feel down in the dumps or maybe a little complacent with our lives. It is during those moments that we have the choice to do nothing and grow even more unhappy with our situations, or work toward self–improvement and spark a positive change. One of our favorite ways to jumpstart happier and healthier lifestyles is by reading some amazing and motivating quotes from outstanding individuals. Here are 15 of our favorite inspiring quotes for people with disabilities; we think you'll like them too.


Ever looked at Thaumcraft's armor and wondered why you can't personalise it? Well, wait no longer!
This addon lets you enhance the armor sets in your collection, so you can bring your style with you as you explore. Like the Crimson look, but wish it came in blue, pink, or maybe black? Now it does - or whatever color you choose.
This mod is a continuation/rebuild of EtsyTheDragon's Thaumic Upholstery, who we have to thank for creating the original mod!
Sorry, but I haven't latest version of mod because serverdon't download it. Can you help me? I've got a 1.7.0-4 version.
In that case, they're both Lost research still. So best hope you get lucky doing random research notes.
Glad to hear that you like it!
"Shuffled tab layout around to make space for upcoming content..."
Patience, young padawan. It'll be done when it's done. I'm chipping away at it.
So, sometime this side of the heat death of the universe (i.e. before EE3).
Just follow these simple steps that other modders hate!
Maybe I can get a good start now.
3,5 blocks high jump for a nice parkour experience!
Seeing that you added in the Cultist Ranger armor, are you also going to include the Paladin,Archer and Jester armors?
Maybe if the author of them allows for it.
Submitted an issue on KryptonCaptain/Thaumic-Dyes Github about some infusion recipes I'm unable to get working.
with 1.2 version break a lot of other mods recipe like planks from logs in biomes o plenty.
I'm sorry but i'm sure of what i say. It broke alst better builder wand. It happen every time i add the 1.2 version even in a new testing profile with few mod like thermal expansion thaumcraft and no more. The nei show the correct recipe but the crafting table don't show the result and even clicking nothing happend.


text:
Letter from Lyme Bay
Horatio Morpurgo
Miles Hoskin
Pollution, potting and community action at Lyme Bay all demonstrate that we need to think synoptically about living systems.
The Charmouth Heritage Coast Centre is best-known for the new species of ichthyosaur - unveiled there by David Attenborough - which features in a popular documentary.
The Centre attracts 150,000 visitors a year, mainly during the summer. On a blustery Monday afternoon in November, the beach outside is littered with debris from a recent storm and the place is more or less deserted apart from a small group of locals gathering in a back room.
They are beach-cleaners, surfers, museum volunteers, parents, local councillors, Transition-towners: and they are all here to talk about bio-beads.
Bio-beads
Bio-beads are small plastic pellets which, coated with bacteria, are used as part of the filtration process in some waste-water treatment plants.
The local water company, South West Water (SWW), operates eight plants of this kind and it became apparent, early in 2017, that the beads were escaping in vast quantities.
Five million were removed from a 100m stretch of Tregantle Beach in Cornwall. Thirty-two were regurgitated in a single pellet by a herring gull on the Fal estuary.
The beads – heavily contaminated with cadmium, lead and the bromines used in flame retardants – appear to be made from recycled electronic equipment.
So when bright blue bio-beads began to wash up at Charmouth later in 2017, this was already part of a larger story. When questioned about them, the company argued that it would 'cost too much' to find out what colour beads were being used in their nearest plant, at Uplyme. A spokesperson told a reporter SWW was 'confident that there has been no loss of bio-beads from the site.'
A group of concerned locals was finally admitted to the plant at Uplyme in February 2019 and easily found bright blue bio-beads, exactly matching those on the beach, lying around on the site.
The newly-formed group at Charmouth, Ban the Beads, will be responding to the company on behalf of the communities around the bay.
In a recent statement about its performance in the six months to November 2019, SWW claimed to be both 'reducing pollution incidents' and 'on track to meet our leakage target.'
To judge by the half year report of its parent company, Pennon, it is also on track to turn a profit of nearly £200m at the full year.
A 2019 report from Surfers Against Sewage, meanwhile, places SWW as the third worst company in the country for 'discharge notifications' (i.e. discharge of untreated waste water). On some metrics it is the worst-offending water company in the country and is rated overall as having 'relatively poor performance'.
SWW recently told the Times that any escape of beads is 'unacceptable' and it has now installed secondary screening at all its plants (except the largest one, at Plympton). But the confidence about its record on the environment would appear open to question, at least to those who recall the company's earlier statements.
Limiting fishing
Reporters on the marine environment do not regularly connect stories like this with marine conservation 'proper' but Charmouth of course overlooks the Marine Protected Area (MPA) in Lyme Bay.
The connection here is hard to miss. Established in 2008, with the exclusion of scallop-dredgers from parts of the bay, this remains the best-studied and best-managed of the larger MPAs in UK waters. Fifty-five smaller boats have signed up to a voluntary agreement limiting their fishing effort in the common interest.
There has been, however, an unforeseen consequence of success here. Excluding the dredgers made the area very attractive to potters, who could now set their gear confident that it would not be towed away – and set it, what's more, on a rapidly recovering sea-bed.
The question now arose as to whether commercial potting might begin to damage the very sea-bed we had set out to protect.
Ecological impacts
2019 saw publication of Adam Rees' long-awaited report into these matters. Dr Rees, a researcher at Plymouth University, worked with fishermen to select 16 designated areas within the MPA, each of 500m x 500m, where potting effort was carried on over three years at high, medium or low pressure, with control areas in which there was no potting.
Ross coral and Neptune's heart sea squirt are slow-growing organisms crucial for 'reef-forming', or building up a 'honeycomb' of habitat on the sea-bed.
Their growth encourages the settlement of larvae, offers shelter to young fish and structure for nest-building reef fauna. What the report showed clearly for the first time was that these recovered more slowly where potting intensity was at medium to high.
Rees concluded: 'We have demonstrated evidence of the first known ecological impacts associated with commercial potting.'
Jean-Luc Solandt, of the Marine Conservation Society, agrees: 'Sea squirts filter large amounts of seawater, extracting nutrients, so large-scale unregulated potting will have deleterious impacts to seabed habitats.' Rees' report puts reliable information about this, for the first time, into the hands of fisheries managers.
Synoptic view
Back at the Charmouth Heritage Coast Centre, a new set of panels is being set up. These will form an indoor 'marine area' to raise awareness of the MPA just offshore.
Alison Ferris, deputy senior warden at the Centre and convenor of the group I began with, said: 'Most of the visitors I speak to don't know much about the marine life or that it is a protected area.'
The Centre, she admits, is 'primarily focused on fossils', but big storms now routinely dump large amounts of plastic on the beach: volunteers now lead both nurdle-hunts and beach-cleans. Two of them are monitoring the spread of an invasive sea-weed along the coast.
All of the activities I've touched on here – holding polluters to account, managing an MPA, exploring the geology – these all happen in and around the same bay but in the main are carried on in parallel, each one oddly sealed off from the others.
The Centre's new 'marine area' aims to start putting this right. But isn't there a larger issue here? Might not the present emergency be just the occasion for a new 'synoptic' view of the environment?
A synoptic view would take in all facets of a shared problem and see them not as rivals for attention or funding or prestige but as fellow-contributors to a joined-up solution.
Living systems
Charmouth is on the Jurassic Coast World Heritage Site, most of which runs along the edge of Lyme Bay. The geologist (and local resident) Denys Brunsden first conceived of it as a kind of conservation project.
Brunsden describes how visitors would walk its sequence of rocks, from the Triassic to the Jurassic and the Cretaceous, 'and understanding it, they'll want to look after it.'
Doesn't the same apply to living systems, about which the public also knows more and more?
When an American oil company in the 1990s planned to drill through the reefs in Lyme Bay, both local opposition and the cost of extraction dissuaded them.
Thinking differently
Joan Edwards, a participant in that debate, now Head of Living Seas with the Wildlife Trusts, is in no doubt about the connection between the decisions we make, all of us, in places like Lyme Bay and questions about our wider impact.
Edwards said: 'We are in a climate and environmental emergency. It's right to reduce our carbon emissions. But we shouldn't just think of wind turbines, or even of trees.
'Salt marsh, sea grass and deep-sea mud all absorb more carbon than wood. We've over-trawled and over-dredged the seas for centuries.
'Lyme Bay is what good fishing management can look like. But we need really large HPMAs (Highly Protected Marine Areas). How we use the sea could have a huge role in mitigating climate change. We need to start thinking differently.'
Horatio Morpurgo is a writer and campaigner. His most recent book, The Paradoxal Compass (2017), sets current efforts to protect Lyme Bay in the longer historical context of the West Country's relationship with the sea.
Image: Miles Hoskin.
Lyme Bag


Humanities/Cultural Studies - 3 terms in Second Form Personal Development Seminar I for all Second Form students All Second Form students take 6 classes in the winter and spring (Foundation to the Arts).
Personal Development Seminar II (2 non-credit terms in the Third Form) Third Form Students take 6 classes in the fall, winter and spring. Typically they will take one art and two religion courses.
Humanities/Cultural Studies - 3 terms in II Form Personal Development Seminar II (2 non-credit terms in the Third Form) Third Formers take 6 classes in the fall, winter and spring. Typically they will take one art and two religion courses.
Although coursework from a prior school can be used to determine placement in Lawrenceville courses, it cannot be applied toward meeting Lawrenceville Graduation Requirements.


text:
Dorchester Choral Society has been twinned with Andreaskirche Lübbecke, Germany and L'Orphéon Choir, Bayeux since 1975 and 1992 respectively.
There have been many formative exchanges and the choirs have sung together in pairs alternately in Bayeux Cathedral, Andreaskirch Lübbecke, St. Mary's Church, Dorchester and Milton Abbey.
In 2013, all three choirs joined together to sing Brahms German Requiem in Lübbecke and in 2014 all three choirs joined together in Dorchester to commemorate the start of the First World War in then in Lübbecke to sing A Child of our Time by Sir Michael Tippett. There was a further joint concert in 2016 which included the worldwide première of a new composition by Stephen McNeff, "Word over All". In 2019 the three choirs joined together for a series of workshops in Dorchester rehearsing works by, amongst others, Handel, Brahms and Fauré which were then sung in a "Three Nations Concert" in the wonderful setting of Milton Abbey.
In April 2023 choir members will be travelling to Bayeux to perform in the Cathedral there with their French and German counterparts.
Dorchester Choral Society is also proud of its outreach work, where, at the end of the summer term, we organise free concerts to entertain audiences who might otherwise not be able to attend a formal concert. In 2020 we organised an outdoor event in Borough Gardens: "Music for a Summer's Evening" which was enjoyed by some 400 people relaxing or picnicking as we sang.
In 2018 we put together our first relaxed concert at the United Church in Dorchester which aims to be accessible to all. We wish to repeat this soon.
We want to encourage young people to encounter and enjoy classical music and, in particular, to experience the fun of singing choral music. We are therefore exploring ways of supporting music making at Thomas Hardye School - Dorchester's local secondary school and sixth form college. We have given some financial support to their own music-making and we look to use former and current pupils from time to time in our orchestras or singing in concerts. In 2020 we founded a "Dorchester Choral Society Scholarship Programme" to enable young singers - predominantly sixth formers - to become full members of the society without cost.
Our first scholar has now moved on to the Royal Northern College of Music.
Our second, and current scholar Stefan Oakes is a young baritone pursuing a career in singing. Growing up in Dorchester, he attended The Thomas Hardye School and discovered his singing voice during sixth form there. He has already performed the role of Pilate in the choir's performance of Bach's St. John Passion in April 2022 and at short notice he took over the demanding solo part in Jabberwocky at very short notice and gave an outstanding performance. We are looking forward to his solo role in the forthcoming concert of Faure's Requiem.
Contact sing@dorchesterchoralsociety.org for more details of scholarship opportunities.


This Boy Was Born With One Leg, But What He Did With It Is Amazing.
Nico Calabria does it all — he's a swimmer, gymnast, and soccer player, and he does it all with one leg. This powerful commercial for Powerade tells his story.
Previous: Japanese Woman Loves Talking To Her Bird, But What The Bird Does Back Is Unbelievable. And Hilarious.


We have been designing and making a friend for the Beast. We had to consider what qualities the friend should have. How would the friends get along? Would they have interests in common? What would the friends enjoy doing together? We decided that they would enjoy baking, gardening, running, swimming and playing. Look at our creations!


My family spent Christmas in Costa Rica a few years ago. We loved the nativity scenes that appear all over the country. Families often create an extensive nativity scene with figurines traversing through moss, small plants, and rocks. The scenes are often displayed in the living room or on the porch where they can remind passersby of the Advent of Christmas. While we missed the scent of a freshly cut noble fir, we delighted in experiencing a different tradition of gathering native plants and decorating your home as a part of the Christmas season.


text:
define(
[
    'models',
    'utils',
    'views/common',
    'views/dialogs',
    'views/wizard',
    'text!templates/clusters/page.html',
    'text!templates/clusters/cluster.html',
    'text!templates/clusters/new.html',
    'text!templates/clusters/register_trial.html'
],
function(models, utils, commonViews, dialogViews, wizard, clustersPageTemplate, clusterTemplate, newClusterTemplate, registerTrialTemplate) {
    'use strict';
    var ClustersPage, ClusterList, Cluster, RegisterTrial;

    ClustersPage = commonViews.Page.extend({
        navbarActiveElement: 'clusters',
        breadcrumbsPath: [['home', '#'], 'environments'],
        title: function() {
            return $.t('clusters_page.title');
        },
        template: _.template(clustersPageTemplate),
        render: function() {
            this.$el.html(this.template({clusters: this.collection})).i18n();
            var clustersView = new ClusterList({collection: this.collection});
            this.registerSubView(clustersView);
            this.$('.cluster-list').html(clustersView.render().el);
            if (_.contains(app.version.get('feature_groups'), 'mirantis') && !localStorage.trialRemoved) {
                var registerTrialView = new RegisterTrial();
                this.registerSubView(registerTrialView);
                this.$('.page-title').before(registerTrialView.render().el);
            }
            app.footer.$el.toggle(app.user.get('authenticated'));
            app.breadcrumbs.$el.toggle(app.user.get('authenticated'));
            app.navbar.$el.toggle(app.user.get('authenticated'));
            return this;
        }
    });

    ClusterList = Backbone.View.extend({
        className: 'roles-block-row',
        newClusterTemplate: _.template(newClusterTemplate),
        events: {
            'click .create-cluster': 'createCluster'
        },
        createCluster: function() {
            app.page.registerSubView(new wizard.CreateClusterWizard({collection: this.collection})).render();
        },
        initialize: function() {
            this.collection.on('sync add', this.render, this);
        },
        render: function() {
            this.tearDownRegisteredSubViews();
            this.$el.html('');
            this.collection.each(_.bind(function(cluster) {
                var clusterView = new Cluster({model: cluster});
                this.registerSubView(clusterView);
                this.$el.append(clusterView.render().el);
            }, this));
            this.$el.append(this.newClusterTemplate());
            return this;
        }
    });

    Cluster = Backbone.View.extend({
        tagName: 'a',
        className: 'span3 clusterbox',
        template: _.template(clusterTemplate),
        templateHelpers: _.pick(utils, 'showDiskSize', 'showMemorySize'),
        updateInterval: 3000,
        scheduleUpdate: function() {
            if (this.model.task('cluster_deletion', ['running', 'ready']) || this.model.tasks({group: 'deployment', status: 'running'}).length) {
                this.registerDeferred($.timeout(this.updateInterval).done(_.bind(this.update, this)));
            }
        },
        update: function() {
            var deletionTask = this.model.task('cluster_deletion');
            var deploymentTask = this.model.task({group: 'deployment', status: 'running'});
            var request;
            if (deletionTask) {
                request = deletionTask.fetch();
                request.done(_.bind(this.scheduleUpdate, this));
                request.fail(_.bind(function(response) {
                    if (response.status == 404) {
                        this.model.collection.remove(this.model);
                        this.remove();
                        app.navbar.refresh();
                    }
                }, this));
                this.registerDeferred(request);
            } else if (deploymentTask) {
                request = deploymentTask.fetch();
                request.done(_.bind(function() {
                    if (deploymentTask.get('status') == 'running') {
                        this.updateProgress();
                        this.scheduleUpdate();
                    } else {
                        this.model.fetch();
                        app.navbar.refresh();
                    }
                }, this));
                this.registerDeferred(request);
            }
        },
        updateProgress: function() {
            var task = this.model.task({group: 'deployment', status: 'running'});
            if (task) {
                var progress = task.get('progress') || 0;
                this.$('.bar').css('width', (progress > 3 ? progress : 3) + '%');
            }
        },
        initialize: function() {
            this.model.on('change', this.render, this);
        },
        render: function() {
            this.$el.html(this.template(_.extend({
                cluster: this.model,
                deploymentTask: this.model.task({group: 'deployment', status: 'running'})
            }, this.templateHelpers))).i18n();
            this.updateProgress();
            if (this.model.task('cluster_deletion', ['running', 'ready'])) {
                this.$el.addClass('disabled-cluster');
                this.update();
            } else {
                this.$el.attr('href', '#cluster/' + this.model.id + '/nodes');
                if (this.model.task({group: 'deployment', status: 'running'})) {
                    this.update();
                }
            }
            return this;
        }
    });

    RegisterTrial = Backbone.View.extend({
        template: _.template(registerTrialTemplate),
        events: {
            'click .register-trial .close': 'closeTrialWarning'
        },
        bindings: {
            '.registration-link': {
                attributes: [{
                    name: 'href',
                    observe: 'key',
                    onGet: function(value) {
                        return !_.isUndefined(value) ? 'http://fuel.mirantis.com/create-subscriber/?key=' + value : '/';
                    }
                }]
            }
        },
        initialize: function() {
            this.fuelKey = new models.FuelKey();
            this.fuelKey.fetch();
            app.version.on('sync', this.render, this);
        },
        closeTrialWarning: function() {
            localStorage.setItem('trialRemoved', 'true');
            this.remove();
        },
        render: function() {
            this.$el.html(this.template()).i18n();
            this.stickit(this.fuelKey);
            return this;
        }
    });
    return ClustersPage;
});

redpajama_set_name: RedPajamaGithub


text:
Émile Cahen, né le  à Paris  et mort en 1941, est un helléniste français spécialiste de Callimaque de Cyrène.

Biographie

Frère cadet du mathématicien Eugène Cahen, il est à son exemple élève à l'École normale supérieure de la rue d'Ulm (promotion 1892).

Émile Cahen obtient l'agrégation de lettres en 1895 puis est membre de l'École française d'Athènes de 1896 à 1899, avant d'enseigner à la Faculté des lettres d'Aix-en-Provence comme maître de conférences puis comme professeur. Il consacre sa thèse de doctorat à Callimaque de Cyrène dont il traduit aussi les œuvres.

Il est nommé chevalier de la Légion d'honneur en 1938.

Œuvres

" Les Bouches-du-Rhone " Encyclopédie départementale publiée par le Conseil Général avec le concours de la Ville de Marseille et de la Chambre de Commerce sous la direction de Paul Masson, Première partie : Des origines à 1789, Tome IV (1er volume), Archéologie par Émile Cahen, Robert Doré, Bruno Durand, à la Librairie ancienne Honoré Champion, Paris & Archives Départementales de Marseille, 1932

Traductions

Références

Bibliographie

Liens externes

Helléniste français
Élève de l'École normale supérieure
Membre de l'École française d'Athènes
Naissance en mai 1874
Naissance dans le 11e arrondissement de Paris
Décès en novembre 1941
Chevalier de la Légion d'honneur
Décès à 67 ans

redpajama_set_name: RedPajamaWikipedia


Home » Weekly Menu » Menu for the Week of April 2, 2012 — Happy Easter This Sunday!
Menu for the Week of April 2, 2012 — Happy Easter This Sunday!
This week is special for at least two reasons. First, Sunday, April 8th is Easter. Second, the Masters are this week down in Augusta — another kind of religious experience if you're a golf lover. What does this mean for The Spotted Trotter? It's just two more reasons to get together with friends and family and celebrate health and happiness through food!
If you have your heart set on something you see below for either of these occasions or just for your weekly menu — please remember you can always use our preorder form to reserve your order in advance. At least for the next month, we really encourage everyone to take advantage of this option. As we dramatically increase production to begin our three farmers markets this month, it's going to take all we have to produce enough product, while also ensuring we aren't stressing our local farms by ramping up too quickly. It's a delicate balance, but one we know you, as supporters of local, sustainable food, can understand and even appreciate. Kudos to all of you for being our partner in changing the way this country eats.
We're working on this week's terrines! Please check back!
You can always use our preorder form to reserve your order in advance.


text:
Governor Cuomo Announces Progress and Additional Funding for 'Restore the Gorge' in Niagara Falls
TOP Governor Cuomo Announces Progress and...
Project Controls Invasive Species in the Niagara Gorge
Complements Other State Investments in Niagara Falls State Park and Niagara Falls' Downtown District
Pictures and Maps of the Gorge Can be Found Here
Governor Andrew M. Cuomo today announced that work is progressing to the second phase for on-the-ground ecological restoration work to "Restore the Gorge" in Niagara Falls, including nearly $950,000 in additional Greenway Ecological Fund grants to further efforts to combat invasive plant species and cultivate native plants. The project complements Governor Cuomo's $70 million revitalization of Niagara Falls State Park and other strategic state investments to strengthen the tourism industry in downtown Niagara Falls.
"Niagara Falls is a natural wonder in our own backyard, but the lesser-known Niagara Gorge area is a unique destination that must be protected," Governor Cuomo said. "The ecological restoration of this biologically diverse habitat is critical to supporting the State's ongoing investments that continue to reinvigorate tourism in Niagara Falls and revitalize the entire region."
"Niagara Falls is a gem and one of our great tourist attractions in upstate New York and around the world," said Lieutenant Governor Kathy Hochul, who made today's announcement. "The Niagara River Gorge is one of the most important natural places in the world, and this additional funding will further our efforts to combat invasive species to restore and enhance the natural habitat. This investment complements our support to revitalize the Niagara Falls State Park, various hotel developments, and other projects to increase tourism and grow the economy of Western New York."
The Niagara Gorge was once one of the most botanically diverse places in North America and restoring the native flora will benefit wildlife such as migratory birds, which in turn supports the growth of the Niagara Greenway as an eco-tourism destination. Lieutenant Governor Kathy Hochul gave several native red oak saplings to children following the announcement to mark the occasion.
'Restore the Gorge' is transforming the ecological health of the Niagara River Gorge and Rim by controlling invasive species and planting native trees, shrubs, grasses and flowers in the Niagara Gorge from the Niagara Gorge Discovery Center to Devil's Hole State Park. The Western New York Land Conservancy has been leading the initial phase of efforts to restore and enhance the natural habitat on 37 acres of land along the gorge with an initial $1 million in funding from the New York Power Authority via the Niagara Greenway and the Ecological Standing Committee.
With the addition of $1 million from Empire State Development in January 2017, as well as funds from New York Sea Grant and the Verizon Media Community Benefit Fund for Niagara County (formerly the Oath Community Fund), the Land Conservancy has been able to expand the initial phase of removing invasive species, and is working to restore an additional 48 acres within the gorge and along the rim in Whirlpool State Park. This second installment of Greenway Ecological Fund grants will further advance the project. Land in the project area is owned by the New York Power Authority and by the New York State Office of Parks, Recreation, and Historic Preservation.
Land Conservancy Executive Director Nancy Smith said, "Working in the Niagara Gorge is an extraordinary opportunity to give back to nature in a place that builds community, while showcasing the value of native plants on the world stage. Our efforts will increase biodiversity, provide habitat for butterflies and songbirds, and purify our fresh water. This project will reconnect people with nature and enhance the economic vibrancy of Niagara Falls."
Empire State Development President, CEO & Commissioner Howard Zemsky said, "Our work to expand economic opportunities and improve the visitor experience in downtown Niagara Falls is taking hold, and the efforts underway in the Gorge will further the strategic investments in our State Parks and tourism assets in Western New York."
New York State Office of Parks, Recreation and Historic Preservation Commissioner Erik Kulleseid said, "The work that the Western New York Land Conservancy is doing to restore the Niagara Gorge is monumental. It is work that is important to maintain the health of the gorge and in addition, speaks to how good things happen when you work with partners in the community. I thank Governor Cuomo for his ongoing commitment to Niagara Falls and New York State Parks as well as the New York Power Authority and the Niagara River Greenway Commission."
New York Power Authority Board of Trustees Chairman John R. Koelmel said, "The New York Power Authority is pleased to support the ongoing important work to 'Restore the Gorge' including planting native vegetation and combatting invasive species. When visitors come to Niagara and when residents head outside we want them to enjoy the beautiful scenery and take advantage of the recreational opportunities this area offers. With these Gorge improvements and the parkway removal and trail development we are ensuring that future generations will be able to enjoy these outdoor spaces for years to come."
Niagara River Greenway Commission Executive Director Greg Stevens said, "The Niagara River Greenway is committed to providing a world class trail experience for walking and wellness, and there is nowhere better than the Niagara Gorge to highlight the potential this community has to be a true recreation destination. We will achieve our goal only by working with community groups like the Western New York Land Conservancy and leaders like Governor Cuomo."
Congressman Brian Higgins said, "The Western New York Land Conservancy is leading the way on identifying, preserving and enhancing unique pieces of Western New York's natural landscape. The Niagara Gorge is a destination like none other. This additional investment of Niagara Greenway money, made possible through the relicensing settlement with the New York Power Authority, will build on New York State's significant investment in Niagara Falls."
Senator Rob Ortt said, "The 'Restore the Gorge' project is a vitally important endeavor that will see the natural beauty and diverse ecosystem surrounding Niagara Falls continues to flourish. As home to one of the natural wonders of the world, our community is tasked with protecting and nurturing a landscape that is responsible for drawing millions of travelers from around the globe. I am proud that we have recognized the importance the falls and the wildlife surrounding it has on our region and we must work together to ensure this scenic environment continues to thrive for generations to come."
Assembly Member Angelo Morinello said, "Thank you to the Western New York Land Conservancy for recognizing the need to restore the gorge to its natural wonder. The removal of invasive species and the replanting of native species will go a long way toward fostering the long term health of the Gorge as well as opportunities for ecotourism."
City of Niagara Falls Mayor Paul Dyster said, "This is a transformative time for the City of Niagara Falls with unprecedented growth not seen in many years taking shape before our very eyes thanks to Governor Cuomo and projects like the gorge restoration. Thanks to the efforts of the Western New York Land Conservancy, the Niagara Gorge will continue to enrich the visitor experience as one of the most biologically diverse ecosystems for many years to come."
As one of the most biologically diverse places on the Great Lakes, the Niagara Gorge is home to unique ecological communities, including many rare plants, and is part of a globally significant Important Bird Area. The lower Niagara River rapids are important spawning grounds for freshwater fish including threatened Lake Sturgeon. The health of this sensitive environment has been harmed by many factors, especially non-native invasive plants. The Land Conservancy has hired Applied Ecological Services to remove harmful invasive plants like Norway maple, common buckthorn, tree-of-heaven, and phragmites for the first phase of the project. These invasive species are being replaced with beneficial natives like oak trees, ninebark shrubs and Canada anemone.
The native red oak saplings given to children today by Lieutenant Governor Hochul were grown from locally-collected acorns at New York State Parks' Western Region Native Landscape Greenhouses at Knox Farms State Park. Gifting these Western New York native trees is symbolic of the region's growing commitment to careful stewardship of the earth and supporting Western New York natural landscapes.
The 'Restore the Gorge' project is the latest example of New York State's commitment to maximize the City of Niagara Falls' true potential as a world-class tourist destination. Other projects supported by the State include $70 million in recent renovations to Niagara Falls State Park; more than $73 million dedicated to the removal of underused expressway segments; multiple completed, in progress and planned hotel projects; the acquisition of a number of key underutilized properties within close proximity to Niagara Falls State Park for mixed-use development; and $172 million in public and private development in downtown Niagara Falls completed under Governor Cuomo with an additional $264 million in projects underway and proposed. 'Restore the Gorge' builds on the ecological and recreational improvements that will be gained through the removal of the Niagara Scenic Parkway.
During the multi-year project, there will be trail closures for the safety of visitors to this area in the Niagara Gorge. Trail closures will be temporary and intermittent while crews are working in areas that may cause rocks or debris to fall. These closures will only occur during daytime hours on weekdays and trails will not be closed on weekends. A list of closed trails can be found here.
About Western New York Land Conservancy
The Western New York Land Conservancy is a regional, not-for-profit land trust that permanently protects land with significant conservation value in Western New York for current and future generations. The Land Conservancy envisions a future in which open spaces, working lands, wildlife habitat, and scenic beauty are cherished and protected as part of the landscape and character of Western New York. The Land Conservancy is accredited by the Land Trust Accreditation Commission and is one of 1000+ land trusts nationwide, including 90 in New York State. Land trusts have protected 56 million acres of land. For more information on upcoming events, volunteer opportunities, or the mission of the Land Conservancy, please call (716) 687-1225 or visit https://wnylc.org/.


text:
Q: Rest api - create customer I follow this Magento guide to work with Magento API REST (New Learner):
http://devdocs.magento.com/guides/v2.2/get-started/order-tutorial/order-create-customer.html
In this step I try run this curl line to create a new customer:
curl -X Post "http://domain/api/rest/default/V1/customers"\
    -H "Content-Type:application/json"\
    -d '{"username":"example", "password":"example"}'

and get "curl: (6) Couldn't resolve host".
Also I want to ask, can I call this request with Postman?

A: You can try this command:
token=$(curl -X Post "http://domain/rest/V1/integration/admin/token"\
-H "Content-Type:application/json"\
-d '{"username":"<admin_user>", "password":"<admin_password>"}')\;
curl -X POST "http://domain/rest/default/V1/customers"\
-H "Content-Type:application/json"\
-H "Authorization:Bearer "$token\
-d '{"customer":{"email":"example@example.com", "firstname": "Example", "lastname": "Example", "id_card": "123456", "tos": "Yes"},"password":"12345678"}'

Explain: according to the official document you provided,
token=$(curl -X Post "http://domain/rest/V1/integration/admin/token"\
-H "Content-Type:application/json"\
-d '{"username":"<admin_user>", "password":"<admin_password>"}');

is getting admin token, and then store the result to a variable called $token. And then
curl -X POST "http://domain/rest/default/V1/customers"\
-H "Content-Type:application/json"\
-H "Authorization:Bearer "$token\
-d '{"customer":{"email":"example@example.com", "firstname": "Example", "lastname": "Example"},"password":"12345678"}'

is creating customer part.
I've tested this on M2.1.7, but should be more or less the same on M2.2.

redpajama_set_name: RedPajamaStackExchange


Federal Housing Administration (FHA) loans can be an excellent choice for first-time homebuyers, as well as those who have very little money to put down on a house. They do operate differently than conventional mortgages, which is why you should know a little bit about them before applying.
FHA loans are ones that are insured by the department of Housing and Urban Development (HUD), which allows approved lenders to offer more favorable terms. Contrary to popular belief, they are not financed through the Federal Housing Administration, meaning you will still make your payment directly to the lending institution as you would with any other mortgage.
Have a credit score of at least 640.
Wish to occupy the property as your primary residence.
Be considering a single family property, or a townhouse, apartment, or condo with no more than four familial units.
Have a minimum down payment of 3.5%.
Be able to provide an employment history for at least the past two years.
Earn sufficient income so that your debt-to-income ratio is no more than 43%.
FHA loans are generally not available to those who have had a foreclosure or bankruptcy within the past two years. In addition to waiting 24 months, you will also need to demonstrate that you are "turning over a new leaf" by keeping all payments current and avoiding any negative reporting to the three major credit bureaus.
All FHA mortgages are subject to an impound account, which is similar to an escrow account. The cost of your property taxes and homeowner's insurance will be broken down into monthly payments and added on to the cost of your mortgage. The additional amount is then placed into the impound account, and used to cover your property tax and insurance premiums when they come due.
You will also pay an Upfront Mortgage Insurance Premium of 1.75% at the time of closing. In addition, an annual mortgage insurance premium of between .25% and .65% is tacked onto your mortgage, and is calculated as an additional amount monthly along with your impound account.
The Federal Housing Administration's "floor limit" for housing is $275,665 in 2017. This is the minimum loan limit available in all parts of the country for a single-unit home. Some counties throughout the country have higher maximums based upon the local market. Your regional HUD office can provide you with more information concerning local limits. The national HUD counseling line is also a valuable resource for finding out more about FHA loans in general, and may be reached at 800-569-4287.
Thousands of people are able to realize their dream of home ownership each year thanks to affordable loans insured by the Federal Housing Administration. If you are struggling to come up with a down payment, now is the time to find out whether or not one of these loans is right for you.
This entry was posted in Blog and tagged fha, mortgage by Scott Li. Bookmark the permalink.


To Cite: Liu X, Gao Y, Niu J. Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents, Hepat Mon. 2018 ; 18(6):e66007. doi: 10.5812/hepatmon.66007.
Context: The emergence of direct - acting antiviral agents (DAAs) with high sustained virological responses (SVR) is an epoch - making revolution. However, the value of antiviral agents in the field of hepatitis C - related hepatocellular carcinoma (HCC) is not clear. Further, the risk of tumor occurrence or recurrence following an antiviral regimen is not yet reached a consensus.
Evidence Acquisition: All scientific evidence was collected through a systematic review of studies discussing DAA regimen and hepatitis C-related HCC, in PubMed, EMBASE, and Web of Science. The relevant articles were obtained and reviewed carefully before working on the paper.
Results: The current review study aimed at discussing recent studies on hepatitis C - related HCC in the era of DAAs, including application of DAAs in the field of treatment of hepatitis C virus (HCV), efficacy of DAAs on HCV-associated HCC, and the effect of DAAs on occurrence and recurrence of HCC.
Conclusions: It was shown that DAAs had a relatively poor therapeutic effect on HCV patients with HCC, based on the current studies. After analyzing the existing data, the conclusion cannot yet be reached that DAA treatment influences the risk of HCC in patients with HCV infection.
According to the latest World Health Organization (WHO) statistics, 71 million people worldwide have chronic hepatitis C (CHC) (1), and approximately 60% - 80% of the patients with hepatitis C are in a state of continuous viral infection (2). Due to the biological characteristics of HCV, host immune - function differences, and other factors, HCV has a higher risk of cirrhosis (3) and hepatocellular carcinoma HCC (4). Studies showed that HCV infection causes a 15- to 20 - fold increase in the risk of developing HCC. The incidence of HCC is 3% - 5% per year in the HCV population with cirrhosis (5). Among HCV - infected individuals, Asian patients (primarily Southeast Asian) are older, have lower body mass index (BMI) values, and are more likely to be in advanced liver diseases with a greater chance of progression to HCC in the event of cirrhosis (6, 7). In the United States, approximately 50% - 60% of the patients with HCC have chronic infection of HCV (8, 9), whereas in China, HCC is mainly caused by infection of hepatitis B virus (HBV). Authors' previous study showed that seroprevalence of anti - HCV antibodies was approximately 16% (10). The mortality of HCC in the United States increased by 72% from 2003 to 2012 (11), and the main cause of carcinoma was long-term HCV infection (12-14). At present, the number of patients with viral hepatitis - related HCC in China is large; however, with the popularization of HBV vaccine and the success of mother - infant blockage, the composition of the etiology of HCC changes. The field of HCV - related HCC is of increasing concern, and antiviral treatments are the key to HCV - related liver diseases.
Since 2011, oral direct - acting antiviral regimens gradually replaced the traditional interferon (IFN) and had a cure rate as high as 90% or more (15). Prior to this, due to the poor efficacy and contraindications of IFN, anti - HCV treatment in patients with HCC was relatively rare. Recently, with the wide - spread use of direct - acting antiviral agents (DAAs), more and more patients with HCC infected with HCV are trying to continue antiviral therapy with DAAs after receiving standard anti - tumor therapy. However, the efficacy needs to be fully evaluated. In addition, there are different opinions about the effect of DAAs on the incidence of HCC in patients with CHC, especially on the recurrence rate of HCC in patients successfully cured. A considerable number of scholars believe that DAAs may increase the occurrence or recurrence of HCV - related HCC, which is a potentially significant clinical problem. Therefore, the current review study aimed at focusing on the following two research hotspots: the antiviral efficacy of DAAs in CHC patients with HCC and the effect of DAAs on the incidence or recurrence of HCV-related HCC.
To gather data and information for the current review, authors systematically searched for relevant articles that described the relationship between DAAs and HCV - related HCC, in PubMed, EMBASE, Web of Science with date limitation (within 10 years). Free text words and MeSH terms were used along with Boolean operators such as the following keywords in the search: hepatitis C, viral hepatitis, viral liver disease, hepatocellular carcinoma, HCV - associated HCC, hepatitis C - related HCC, direct - acting antiviral agents, DAA, etc. A review of the title and abstract of studies identified in the search was performed to exclude studies that did not answer the research question of interest. Full texts of the rest of the articles were then examined to determine whether they contained the sought data. After browsing the full texts, clinical studies were included in the current review study except for the ones with the following conditions: 1) non - English articles; 2) studies on liver diseases other than hepatitis C; 3) HCC that occurred not based on HCV; 4) studies on antiviral treatments other than DAAs.
The pharmacological mechanism of traditional IFN is that IFN binds its receptors to the cell membrane, turning on a signaling pathway that activates transcription factors called IFN regulatory factors, which induce the host to produce IFN - stimulated gene (ISG) products and inhibit the virus. Proteases, helicases, and RNA polymerases are non - structural proteins that are targets for DAAs. However, due to the rapid development of resistance mutations in HCV to a single drug, monotherapy cannot be used to treat HCV.
Effective antiviral therapy allows patients to achieve sustained virological responses (SVR), which can reduce the incidence of HCV - related complications, liver transplantation, and even death (16, 17). The partial response (PR) regimen of peginterferon - α (PegIFN - α) combined with ribavirin (RBV) used to be the standard of care for HCV (18). The SVR rate of patients in China with HCV treated by the PR regimen ranged 44% to 83% (19). However, the standard course of this regimen was relatively long, had significant side effects, and was better to treat non - genotype 1 HCV; whereas, genotype 1b infection was predominant in Chinese patients (20). In addition, antiviral therapy with IFN had a high recurrence rate (approximately 30%) (21). When non - responders with genotype 1 were re - administered a high-dose PR regimen, the SVR rate was less than 18% (22).
DAAs are small - molecule compounds for therapies targeting viral proteins in the life cycle of HCV. The first NS3/4A serine protease inhibitor was approved by the United States Food and Drug Administration (FDA) in 2011, and a total of 10 drugs were approved from 2011 to 2016. Daclatasvir (DCV) combined with asunaprevir (ASV) was the first DAA regimen approved by China in 2017 to treat genotype 1b CHC (non - cirrhosis or compensated cirrhosis) among adults. The emergence of DAAs is a revolutionary breakthrough that effectively eradicates HCV in a short period of time, typically 12 weeks, with a high SVR rate (7, 23-25). Further, DCV in combination with sofosbuvir (SOF) improved the efficacy of monotherapy; it was also highly recommended by the European Association for the Study of The Liver (EASL) in 2015 to treat all genotypes of HCV infection.
It is demonstrated that treatment with IFN in CHC patients with HCC brought about survival benefit (26-28), presumably because IFN inhibited the pro - inflammatory and carcinogenic effects of HCV through anti - inflammatory, anti - angiogenic, and antiviral functions. However, a lower SVR rate and certain side effects limited the use of IFN, and patients with decompensated cirrhosis could not use IFN for antiviral therapy (21). Nowadays, the approval of oral DAAs regimens extends the clinical treatment of HCV to HCV - related cirrhosis with HCC. However, until now, the data on the efficacy of DAAs in patients with HCV - related HCC are limited. Over the past two years, related studies appeared in China and other countries.
In the area of DAA therapy for HCV - associated HCC with or without cirrhosis, Chang et al., published a cohort of Asian - American patients (N = 110) in 2017 showing that an overall SVR12, defined as having no detectable HCV RNA upon polymerase chain reaction (PCR) 12 weeks following the end of treatment, was as high as 93% after an IFN - free SOF - based regimen compared with only 82% in 17 patients with HCC (29). Coincidentally, in the study by Prenner et al., a total of 421 CHC patients with cirrhosis were identified, of whom 33% had active HCC or a history of HCC. The team found that after DAA therapy, CHC patients without HCC had an SVR of 88% compared with 79% in the ones with HCC; the differences were statistically significant. Of the patients with HCC who did not achieve SVR, 93% had an active tumor. DAA therapy achieved a significant SVR rate in the presence of an inactive tumor or after removal of tumor, similar to the patients without HCC. After multivariate analysis, the primary predictor of failure for DAAs was the initial presence of active HCC (30).
Recent studies showed that the effect of DAA therapy on HCV - related HCC can be corrected by liver transplantation (LT). The report by Beste et al., published in the Journal of Hepatology supported this point of view. Of 17,487 HCV - treatment recipients, 624 had prior HCC, including 142 who underwent LT (HCC/LT) and 482 with no LT (HCC/NLT). The results showed that overall SVR was up to 91.9% in CHC patients without HCC and 93.4% in HCC/LT, but only 74.5% in HCC/NLT after DAA therapy. For different genotypes of HCV, efficacy of DAAs is different. In patients with HCC, the highest SVR (HCC/NLT 79.0% vs. HCC/LT 96.0%) was obtained for genotype 1 and the lowest for genotype 3 (HCC/NLT 47.0% vs. HCC/LT 88.9 %) (31, 32).
It is not yet clear why HCV - related HCC had lower SVR rates compared with CHC without HCC when the selected studies were analyzed. Presumably, the presence of a tumor induces the long - term inflammatory response, which leads to the disruption of normal liver structure and alters the microenvironment of cytokines and chemokines (33, 34); thus, affecting the process of the intrahepatic immune response. In addition, patients with HCC are mostly at the cirrhosis stage, and the burden of advanced liver disease increases the difficulty of antiviral therapy. By contrast, LT corrects disorders of liver function and removes potential tumor cells, thus achieving high SVR in patients with HCC after transplantation. Patients with LT generally have a strong desire for survival and good compliance; therefore, they may better comply with antiviral therapy (35, 36). Based on the current study results, it was demonstrated that DAAs had a relatively poor therapeutic effect on HCV - associated HCC.
The availability of highly effective, oral antiviral regimens, which gradually replaced IFN - based antiviral therapies, changed the treatment options for patients with CHC. Most of these patients are fortunate enough to achieve virus clearance; however, clearance does not represent a cure for CHC - associated liver disease. In addition, studies showed that HCV RNA persists in the liver and peripheral blood mononuclear cells in some sustained viral responders (37). Patients with cirrhosis after HCV clearance still require comprehensive treatment to delay the progression and complications of cirrhosis. As a matter of fact, it can be observed that the benefits of virus removal increases patients' survival rate and avoids complications. For the clinical application of new DAAs, more time is needed to observe their safety and their correlation with the occurrence or recurrence of HCC. Initially, some scholars believed that the DAA therapy for patients with HCV infection can reduce the risk of HCC, but there were also many studies emphasizing the use of DAAs in patients with decompensated cirrhosis after viral clearance in which the occurrence or recurrence of liver cancer may increase, resulting in queries on such treatments (38). Previously, due to the immunostimulatory and anti - tumor effects of IFN, this phenomenon was never observed in IFN - based HCV treatment.
Several studies discussed DAAs and de novo HCC, the individual study details are outlined in Table 1. An uncontrolled study from the United States followed the outcomes of 66 patients with cirrhosis who achieved an SVR using DAA therapy. Ravi et al., observed an occurrence of de novo HCC in about 9% of the patients during or within six months of DAA therapy (39). DAA therapy seemed to increase the de novo occurrence of HCC among patients with HCV - related cirrhosis (40). However, other studies showed opposite conclusion (41-43). For example, Li DK et al., performed a retrospective population - based cohort of 17,836 individuals; the results showed that DAA therapy was not associated with a higher risk of HCC in cirrhotics with CHC in the short - term (44). Ioannou et al., reported, after analyzing the association between SVR and HCC risk and between the type of antiviral regimen and HCC risk by the Cox proportional hazards, that DAA - induced SVR was associated with a 71% reduction in HCC risk, and treatment with DAAs was not associated with increased HCC risk compared with the treatment with IFN (45). Cheung et al., from Queen Mary University of London, found that nearly one - third of the newly detected liver cancers developed in patients occurred early, within three months of commencing DAA treatment, suggesting it as an event of cancers that were radiologically undetectable at treatment baseline rather than de novo development, in other words, rather than induced by drugs (46).
Abbreviations: 3D, 3 - drug combination paritaprevir/ritonavir/ombitasvir plus dasabuvir; ASV, asunaprevir; DCV, daclatasvir; LDV, ledipasvir; RBV, ribavirin; SIM, simprevir; SMV, simeprevir; SOF, sofosbuvir.
When these previously published studies were consulted, issues were as follows: smaller sample size, shorter follow - up period, and lack of controllability in retrospective cohort studies, which may bias the outcome. Recently, Ji et al., from the Beijing 302 Hospital of China presented a new prospective study at the 52nd EASL (the European Association for the Study of the Liver). A total of 1498 patients were enrolled in the study. After screening for exclusion criteria, 397 patients treated with IFN and 324 patients treated with DAAs were enrolled. The patients were followed for an average of 12 - 36 months. The incidence of HCC did not significantly increase in either group. The study, with the prominent features of a longer follow - up period and more patients aroused heated discussions. Other successively published prospective studies that included tumor occurrence also supported Dr. Ji's point of view. Nagaoki et al., after a relatively long observation period, showed that carcinoma development after HCV eradication was similar between the patients treated with the PR regimen and DAA therapy (49).
Since approved in 2011, it is believed that DAAs are still generally used for a short time; however, the occurrence of HCC is a long - term and potentially ongoing process. Changes at cellular or molecular levels may occur 1 - 2 years prior to an imaging diagnosis of cancer. After summarizing the main work throughout these researches, it should be clarified that DAA - treated groups were usually confined to the ones with failure of IFN treatment or contraindications for IFN administration such as decompensated liver cirrhosis. While initial liver diseases were more serious and risks of developing cirrhosis were higher in such population, they had a higher risk of HCC occurrence, possibly leading to bias of results that could interfere with discussions of the effects of DAAs on HCC. Therefore, as proven by previous studies, there is ample body of evidence now that the risk for de novo HCC development in successfully treated cirrhotic patients is not increased, when data are properly adjusted to the stage of disease.
Although the risk of HCC after a DAA regimen is of great concern, some scholars considered that this risk is primarily aimed at patients with a previous HCC (50). In other words, DAA may have an influence on tumor recurrence. Relevant studies are summarized in Table 2. Reig et al., published a retrospective cohort with small sample size (N = 58) (51); 58 patients with prior carcinoma meeting the inclusion criteria received DAAs. After a median follow - up of 5.7 months, three patients died and 16 developed radiologic tumor recurrence (27.6%). The data showed an unexpectedly high rate and pattern of tumor recurrence coinciding with HCV clearance. Other studies (52, 53), with similar results, held the shared view that patients receiving DAAs had a greater risk for the recurrence of HCC. Conti et al., also found that after DAA therapy, 17 of 59 (28.8%) patients had HCC recurrence, whereas only nine of 285 (3.16%) patients were diagnosed with HCC for the first time (47). Scholars emphasized on the issue that DAA therapy may increase the recurrence of tumors and speculated that in the process of eliminating HCV, DAAs may induce the tumor by changing the immune status of the host. It is well - known that CHC activates an intrahepatic immune response, leading to increased expression of ISGs and activation of natural killer cells, the most prevalent innate immune cell in the liver. After the DAA therapy, with the clearance of HCV followed by the retreat of immune surveillance, C - X - C motif chemokine (CXCL) 10, CXCL11 decreased, and vascular endothelial growth factor increased significantly, which supported tumor development (54), contributing to the proliferation of isolated tumor cells (55). Therefore, it is suggested that rapid changes to the immune surveillance system and/or anti - tumor response following DAA therapy could be a reason for the apparent increase in HCC recurrence.
Contrarily, the French National Agency for Research on AIDS (ANRS) collaborative study group analyzed individual data from three French prospective multicenter ANRS cohorts and concluded that there was currently no evidence to suggest that DAAs may increase the risk of HCC recurrence (57). A prospective multicenter study by Cabibbo et al., (58) and a retrospective cohort by Huang et al., (56) also showed the risk of HCC recurrence was not higher than that of observed in DAA - unexposed patients. Ikeda et al., even suggested that DAA therapy significantly decreased recurrence rate after adjustment with covariates of tumor multiplicity, alpha - fetoprotein (AFP) value, and prothrombin time on the basis of a multivariate analysis (59). Further, there was a significant decrease in AFP in patients with cirrhosis achieving a SVR with DAAs. Maybe AFP should be further studied as a screening modality for HCC in patients with HCV - related cirrhosis achieving SVR (63). To solve the inconsistency in the findings and increase the statistical power, a statistical analysis of a large collection of research results from individual studies could be more useful. A systematic review published in 2017 provided this summary. A total of 41 studies were included. In a meta - regression adjusting for study follow-up and age, DAA therapy was not associated with higher HCC incidence, and there was no evidence to show differences between DAA and IFN therapy on HCC occurrence or recurrence (64).
Combined with the current researches (48, 60-62), the conclusion that DAAs may increase the risk for early HCC recurrence still needs more large - scale data and prospective studies to confirm. Therefore, the relevant research in the future should consider the following: a large enough sample size, a long follow - up, a prospective study design, and the same baseline. Among them, the most important one is the consistency of disease background in all groups. Since the patients treated with DAAs may be different from the ones using IFN, controlled studies with sufficient sample size are necessary to shed light on this controversial issue. It is noteworthy that due to the current decreasing use of IFN, observational studies using IFN as a control group are no longer easy to conduct. Only the available data can be used as a control. Choosing HCV patients as a study population and ruling out the status of advanced liver disease may prevent the disease itself from affecting the results. Additionally, since withholding DAA therapy in patients with advanced liver disease and HCC may have negative consequences, including a higher risk of decompensation and death, studies on DAA regimen should consider the competing risks of death due to HCC recurrence and decompensated cirrhosis (56). The effects of DAAs on hepatocarcinogenesis, tumor progression, and metastasis should be further studied to fully explain these unexpected clinical observations.
With the advent of DAAs, viruses can be efficiently removed and SVR can be achieved in most patients. However, compared with acute HCV infection, DAAs are less effective when treating CHC patients with HCC. In addition, whether DAA could induce the occurrence or recurrence of HCC in the treatment of HCV is a controversy in China and other countries. After analyzing the existing studies, it cannot yet be concluded that DAA therapy influences the risk of HCV - related HCC, although some prospective studies with larger - scale data indicated that the incidence of HCC did not increase significantly after DAA therapy. Therefore, more prospective studies with homogeneous baseline are still needed to determine the impact of DAA on the occurrence or recurrence of HCC.
Disclosure Statement: There are no conflicts of interest to disclose, in addition, we have not received any financial grants and other funding.
1. World Health Organization. Hepatitis C Fact sheets. [cited October]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6(1):4-14. doi: 10.1177/2040622314551934. [PubMed: 25553238].
3. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809-16. doi: 10.1053/jhep.2001.27831. [PubMed: 11584380].
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061. [PubMed: 17570226].
5. Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229-42. doi: 10.21037/jgo.2017.03.14. [PubMed: 28480063].
6. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37(10):921-36. doi: 10.1111/apt.12300. [PubMed: 23557103].
7. Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2(9):820-4. [PubMed: 15354283].
8. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767-75. doi: 10.1002/hep.27222. [PubMed: 24839253].
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38. doi: 10.1016/j.jhep.2006.05.013. [PubMed: 16879891].
10. Li H. Retrospective analysis of the clinical features of 876 cases of patients with primary liver cancer. Jilin: Jilin University; 2016.
11. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-37. doi: 10.1002/cncr.29936. [PubMed: 26959385].
12. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. doi: 10.1038/nrgastro.2013.107. [PubMed: 23817321].
13. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149(6):1471-82. quiz e17-8. doi: 10.1053/j.gastro.2015.07.056. [PubMed: 26255044].
14. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-30. [PubMed: 11088082].
15. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87-99. doi: 10.1016/j.jhep.2015.02.006. [PubMed: 25920094].
16. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-16. doi: 10.1016/j.cgh.2011.03.004. [PubMed: 21397729].
17. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi: 10.1001/jama.2012.144878. [PubMed: 23268517].
18. Hu P, Ren H. [Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China]. Zhonghua Gan Zang Bing Za Zhi. 2016;24(11):869-73. doi: 10.3760/cma.j.issn.1007-3418.2016.11.015. [PubMed: 27978936].
19. Xiaoyu W, Junqi N. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C. Linchuang Gandanbing Zazhi. 2016;32(9):1699-705.
20. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599].
21. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93. doi: 10.1056/NEJMoa0808010. [PubMed: 19625712].
22. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32(8):969-83. doi: 10.1111/j.1365-2036.2010.04427.x. [PubMed: 20937042].
23. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-93. doi: 10.1056/NEJMoa1316366. [PubMed: 24725238].
24. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705-13. doi: 10.1056/NEJMoa1501315. [PubMed: 26196665].
25. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-14. doi: 10.1056/NEJMoa1401561. [PubMed: 24720679].
26. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17(4):287-92. doi: 10.1111/j.1365-2893.2009.01181.x. [PubMed: 19732321].
27. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58(1):150-7. doi: 10.1002/hep.26300. [PubMed: 23389758].
28. Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study. J Med Virol. 2015;87(7):1199-206. doi: 10.1002/jmv.24173. [PubMed: 25772024].
29. Chang CY, Nguyen P, Le A, Zhao C, Ahmed A, Daugherty T, et al. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine (Baltimore). 2017;96(6). e6128. doi: 10.1097/MD.0000000000006128. [PubMed: 28178174].
30. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173-81. doi: 10.1016/j.jhep.2017.01.020. [PubMed: 28161470].
31. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67(1):32-9. doi: 10.1016/j.jhep.2017.02.027. [PubMed: 28267622].
32. Tammineedi D, Eisert J, Ukken J, Froehlich M, Azab M, Liu X, et al. More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.08.035. [PubMed: 28958883].
33. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27(8):1467-74. doi: 10.1093/annonc/mdw219. [PubMed: 27226385].
34. Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, et al. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016;214(12):1965-74. doi: 10.1093/infdis/jiw457. [PubMed: 27683821].
35. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-17. doi: 10.1053/j.gastro.2014.10.001. [PubMed: 25304641].
36. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485-94. doi: 10.1002/hep.27681. [PubMed: 25557906].
37. MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology. 2009;49(5):1431-41. doi: 10.1002/hep.22802. [PubMed: 19177592].
38. Buonfiglioli F, Conti F, Andreone P, Crespi C, Foschi FG, Lenzi M, et al. Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals. J Hepatol. 2016;64(2). S215. doi: 10.1016/s0168-8278(16)00183-5.
39. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. Gastroenterology. 2017;152(4):911-2. doi: 10.1053/j.gastro.2016.12.021. [PubMed: 28161225].
40. Cardoso H, Vale AM, Rodrigues S, Goncalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65(5):1070-1. doi: 10.1016/j.jhep.2016.07.027. [PubMed: 27476768].
41. Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, Zhang DW, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming? J Hepatol. 2016;65(5):1068-9. doi: 10.1016/j.jhep.2016.07.029. [PubMed: 27476763].
42. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2017;89(3):476-83. doi: 10.1002/jmv.24663. [PubMed: 27531586].
43. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996-1005 e1. doi: 10.1053/j.gastro.2017.06.012. [PubMed: 28642197].
44. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, et al. The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study. Hepatol. 2017. doi: 10.1002/hep.29707. [PubMed: 29205416].
45. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.08.030. [PubMed: 28887168].
46. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65(4):741-7. doi: 10.1016/j.jhep.2016.06.019. [PubMed: 27388925].
47. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727-33. doi: 10.1016/j.jhep.2016.06.015. [PubMed: 27349488].
48. Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, Monari C, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings. World Canc Res J. 2016;3(3). e748.
49. Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, et al. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 2017;12(8). e0182710. doi: 10.1371/journal.pone.0182710. [PubMed: 28797106].
50. Strazzulla A, Iemmolo RMR, Carbone E, Postorino MC, Mazzitelli M, De Santis M, et al. The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real? Hepat Mon. 2016;16(11). e41933. doi: 10.5812/hepatmon.41933. [PubMed: 28070200].
51. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719-26. doi: 10.1016/j.jhep.2016.04.008. [PubMed: 27084592].
52. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65(4):859-60. doi: 10.1016/j.jhep.2016.06.023. [PubMed: 27392425].
53. El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J Viral Hepat. 2017. doi: 10.1111/jvh.12854. [PubMed: 29274197].
54. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, et al. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One. 2016;11(12). e0167934. doi: 10.1371/journal.pone.0167934. [PubMed: 27997563].
55. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol. 2016;13(10):561-2. doi: 10.1038/nrgastro.2016.140. [PubMed: 27580683].
56. Lu Y, Jiang Z, Dai H, Miao R, Shu J, Gu H, et al. Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway. Hepatology. 2018;67(4):1303-19. doi: 10.1002/hep.29633. [PubMed: 29091299].
57. Anrs collaborative study group on hepatocellular carcinoma . Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65(4):734-40. doi: 10.1016/j.jhep.2016.05.045. [PubMed: 27288051].
58. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, Madonia S, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46(7):688-95. doi: 10.1111/apt.14256. [PubMed: 28791711].
59. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, et al. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci. 2017;62(10):2932-42. doi: 10.1007/s10620-017-4739-z. [PubMed: 28884320].
60. Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65(6):1272-3. doi: 10.1016/j.jhep.2016.07.043. [PubMed: 27524465].
61. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 2016;65(4):862-4. doi: 10.1016/j.jhep.2016.05.034. [PubMed: 27255582].
62. Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66(1):236-7. doi: 10.1016/j.jhep.2016.08.016. [PubMed: 27592303].
63. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, et al. Decrease of Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. J Clin Transl Hepatol. 2017;5(1):43-9. doi: 10.14218/JCTH.2016.00057. [PubMed: 28507926].
64. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204-12. doi: 10.1016/j.jhep.2017.07.025. [PubMed: 28802876].


Crochet and Knit - no difference to me.. I only have 2 arms, I can only work on one project at a time. But is there really a snobbery out there where the knitters are more of the "better" crafter? Hmmm... I'm on a Facebook group where I would say 75% of the members crochet. They shop at craft stores vs. LYS. When they shop at the LYS, they feel that the workers there look down on them and are not as friendly once they find out they crochet and don't knit. Really? So, knitters out there.. what do you think of folks who crochet? Well, it doesn't help that they make toilet paper covers!
I took out all the MINI Bugga skeins I have and sorted them... yep, I think I'll have enough to make 192 squares! Although, I have a lot of dark ones..
Anyway, I packed that away... Next, while I have the mini's out... how about I finish the Hexagon blanket?
Nah.. didn't feel like it. How about the blanket where my Mom made the circles and I joined them together?
You see how I lined them up and just up to 3 sides for each circle and then, at the end, I'll join the 4th side?
Pretty smart! Well, I went from 48 squares to start with and ended up with 70 squares joined.
And then, I packed it away. Then, the package came! It came exactly 1 week from when I ordered it from UK. With the strong US dollar, it ended up, with shipping, $2.20 a skein of 100 gr (322 yards of DK acrylic). It is very soft and I haven't found anything here that is equivalent to it - for sure not at that price. This is the yarn that Lucy from attic24 uses. She even has her own selection at Wool Warehouse. There are over 80 colors to choose from. I trust Lucy's selections and ordered the Cottage kit for the Ripple Blanket. My intention was not to make the Ripple basket. I just want to test out the yarn and make some granny squares.
Then, as I was chatting with Jennifer via texting, she ordered 2 kits and I ordered another kit.. We are bad for each other, but luckily, this is cheap yarn! The next morning, I started the Ripple blanket.
I think I need 12 repeats of the 4 colors.. Each color takes about 20 minutes to complete. So say, 90 minutes for 4 colors, I have completed 1.5.. so 10.5 repeats left and 1.5 hours each repeat...about 16 hours... Yep - faster than the knitted one. Crochet On!!
OK - am I done with my crochet stories and move on to knitting?
I worked on my Monkey Socks. Must knit Monkey socks for the upcoming Year of the Monkey.
This week, I will continue to work on the shawl, socks, baby blanket, and oh yes, my Temperature Blanket. I'm now on the second row!
And I found another UK knitter with beautiful crochet blankets. Will be adding her blog to my list on the right. She's Heather from The Patchwork Heart. Jennifer - if you go to the October 23, 2015 post, you will find all sorts of details regarding the Willow block.
Hope those of you are enjoying the snow safely out east. Here in Minnesota, this knitter is not getting enough snow. It's just starting to snow now - maybe we will get 2 inches if we are lucky.
This past week, I spent more time on crocheting than knitting. Yes, I'm hooked (pun, intended). As you know, I started the Temperature blanket. Luckily for a cold spell last weekend, I managed to get the Aqua in. So, this was the chart I worked out... Sometime before we hit the upper 30's, I think I need to move the Magenta further down so I'll have to come up with a new chart.
As you can see in the chart above, I had recorded the daily temperatures in a blank notebook. I was looking for a crochet pattern book at Barnes and Noble and noticed that the calendars were at 50% off. Duh! I decided to buy a Sierra Club calendar - just loved the photos in there and now, I don't have to write the dates!
By next week, I will be going into the second row! I'm getting a little bored already, but I can manage 10 minutes each day to make these squares. If not, maybe over a weekend, I should be able to catch up on a week's worth of squares. I get my temperature history for my city at wunderground.com - I record the actual high and low temp. What I am still trying to decide is when I go to Hawaii and Alaska in March and June, do I record the temperature of where I'm at? Or of my hometown? I'll decide when I get there, or I'll record both and when I get back, I'll see which looks nicer..
(I'm not mentioning the Mitered Squares because that's not crochet!). So I have enough blankets to play with, don't you think? NOT!
I wanted one with solid squares. So I started with a solid granny from attic24. It was too small. It was just about 2.5" and I would have to make thousands of them!
I wanted a stained-glass look so I would like to join these squares with black.. I tried a sample and I'm not sure if the black is enough.. Do I need to add a row of black to each square? (UGH!) or maybe using a thicker yarn? The Bugga is definitely softer than the Bugga used on the Hexagons - maybe it's because of the stitches. Most of the stitches on the Hexagons are double crochets and here, 1/2 of them are half double crochets. But a light weight Merino Wool-Cashmere-Nylon blanket is not a bad thing!
Another idea is if I do the darker yarn on the inside square, the black would show up better, but both Jennifer and my non-crafter-hubby likes the lighter color on the inside... I also don't like to only be able to join AFTER I have all the squares for the blanket. I could wait until I have 2 rows of "all the squares" for the row to start joining.
Also - the British ladies all seem to use this Stylecraft DK yarn for their crochet. I think it's 100% Acrylic and I don't know there are equivalents to them here at Joann's or Michael's.. they certainly don't have their colors! The Vanna's Choice is actually Aran weight, not worsted that I thought. Lucy at attic24 has a site to be able to order some colors she's put together. With shipping to the US, it comes up to about $40 for 15 skeins - still reasonable at less than $3 per skein, 100 gr. I did find a US supplies at $3.09 a skein before shipping. Maybe that's the way to go.. And oh, I also am very attracted to the Sunburst pattern: (maybe I need the Stylecraft yarn for this - pick a few shades and just randomly make the same thing with different shades? I'm hooked, I tell ya.
Frankie, Alicia, and Susan are still reading my blog. I think Jennifer may also be reading this... I did a drawing and Alicia is the winner! I will contact you for your mailing address!! Thank you for not giving up on me!
So in the last few days, I decided to start a shawl. With some many kits and options, I decided on Skipping Dots. I bought Baah! yarn when the proprietor, Mira Cole, was at my LYS doing a trunk show. I wished I took a photo of the finished shawl, but I didn't. Anyway, I'm almost done with the second section. I'm doing an extra 2 repeats for each section. This is more neutral than my usual selection, but as long as there is blue in it, I'm good to go.
The two on the left are Manhattan - 400 yards, MCN. The blue is Platinum, 330 yards with some silver bits in it.
The Hazel Knits group in Ravelry is starting the January/February KAL. Being this year is going to be the Year of the Monkey (yep, my husband will be 60, my son will be 24 (not until 2017 as he is a young Monkey born near the end of the Lunar calendar) - I have 2 Monkeys in the house!), we can knit Monkey socks in HK yarn. And you know that can get me back to knitting socks, right? I'm going to use one of my coveted Multi colored HK yarns in Grape Harvest.
Since Cookie A is on sabbatical, we can knit any of Cookie's February socks released in the last few years. I'll pick up my Bjork Socks I started a year ago.. I think I used Hazel Knits Entice on this one.
You like my journal of the many colors??? This is cheap Acrylic. That way, if I give up, I don't feel so bad. The yarn usually $3.99 a skein. It was on sale for $2.29 plus an additional 20% off due to my overall purchase. So it costs about the same price as a skein of Bugga. HAHA!
I swatched out a square.
And this was 4". I really wanted to border everything in white, but 4" will make the blanket too big. so I opt for one size up for the hook and stay at 2 rows, which was at 3". There are 366 days next year, plus 12 white squares to mark the beginning of the month so I will have 378 squares - exactly 18 per row times 21 rows. I approximated my temperature range and came up with these 2 colors (low of 17, high of 30) for yesterday.
The Aqua didn't really fit in so I'm going to use it when it's -5 degrees Fahrenheit. I don't like the bright red at the end.. I'm assigning it to > 100 degrees. These 2 colors were what I had from before - I was going to make a baby afghan with those colors.
So, Jennifer - won't you join me since you want to get into crocheting?


The Volkswagen Atlas Tanoak pickup truck concept makes its world debut today at the New York International Auto Show.
Volkswagen is about to ignite the next stage of its global SUV strategy. After recently showing the new Touareg in Europe and China, Volkswagen is now debuting a new version of the Atlas SUV at the New York International Auto Show: the Atlas Cross Sport concept.
Volkswagen of America, Inc. announced today that it will offer the R-Line® package on the 2019 Volkswagen Arteon. The new trim package augments the all-new four-door coupe's sportiness with interior and exterior design elements that give it an even more dynamic appearance.
Volkswagen of America, Inc., announced today that it will be building a new five-passenger SUV at its Chattanooga factory. Based off Volkswagen's award-winning MQB platform, the new Volkswagen SUV will be a variant of the seven-passenger Atlas and, like its sibling, will be designed and engineered for the American market.
Next week in Geneva, Volkswagen will unveil the fourth I.D. concept car, the I.D. VIZZION.


Located about 8 km from Airlie Beach is the small village of Shutehaven, nestled on the busy Shute Harbour. Part of the Whitsundays region, Shute Harbour is the main departure point for visitors to the wonderful Whitsunday Islands and surrounding marine parks.
In 1959, when Shute Harbour was adopted as a main tourist terminal, the Government of the day decided to recoup part of the cost by selling off some of the adjacent Crown land for residential development. As a result the official name 'Town of Shutehaven' was nominated and accepted by the Proserpine Shire Council in October 1960. With the debate that ensued from the excising of crown land, a compensation area near Flame Tree was resumed and added to the Conway National Park.
In Shutehaven there is car parking for day trippers and secure undercover parking facilities for people who are spending more time out amongst the Whitsunday Islands. Facilities at the village include an information and check in desk for departures, public phones, toilets, bus parking bays, public transport to/from Shute Harbour to Airlie Beach and beyond, taxi rank and cafe for visitors waiting for their scheduled departures.
Water Taxis are available, as are charter facilities. A claim to fame for the area is that the harbour itself is now home to the largest sea plane airbase in the southern hemisphere, as well as laying claim to being the second busiest harbour in Australia.
The name 'Shute' first appeared when 'Shute Island' was named during a survey by Captain J. F. L. P. Maclear, RN on the HMS Alert around May 1881. The origin of the name was thought to be one of the crew above HMS Alert, although at the time there were at least five people by that name of Shute in the Royal Navy, with no conclusive evidence of which one was above the Alert at the time.
During the period that followed 'Shute Isles' was used in relation to the islands of Shute, Tancred and Repair as they are known today, and sometimes the name was misspelt as 'Schute'. During the survey in 1881, the channel between the three islands and the mainland to the west was named Rooper Inlet after Lieutenant Henry E. Rooper, RN aboard the HMS Alert.
The name 'Shute Bay' was named in 1932 for the waters at the northern end of Rooper Inlet, during a survey of the region in what today is known as 'Shute Harbour'. In fact Shute Harbour was used locally to refer to the region of waters around Shute, Tancred and Repair Islands, as well as including Rooper Inlet and Shute Bay for many years. It had already become popular area for boating, picnics and holiday camps.
In the late 1950s the name 'Shute Harbour' was put forward, but was defeated in the Proserpine Shire Council on 22 August, 1960 and again in October of the same year, with a majority in favour of retaining the names Rooper Inlet and Shute Bay. It wasn't until 11 March 1985 that the council acceded to the Department of Harbours and Marine to name the waters as 'Shute Harbour'. In April 1986 the name became official, with the harbour encompassing all the waters west of a line joining The Beak, White Rock and Stripe Point on the mainland.
Conway Range National Park • The forest provides the perfect environment for many rare species of ferns and orchids (epiphytes), mammals, birds and insects. The Proserpine Rock Wallaby an extremely rare and endangered species resides in the northern part of the park. The giant stinging tree is another resident in this park. Brushing against this tree will give you an extremely nasty sting for a few hours.
• Proudly Australian owned, Fantasea Cruises is the largest day cruise operator in the region, serving the magnificent Whitsunday Islands and the Great Barrier Reef. Our fleet of modern air conditioned high-speed catamarans provide a smooth and comfortable passage to the Outer Great Barrier Reef and throughout the Whitsunday Islands.
• Whitsunday Islands Sailing Holidays - Whitsundays - Whitsunday Islands sailing holidays or bareboat charter in Australia's island paradise with Holiday Magic Travel.